NVO240705C144000
- 0.01
- -0.10-90.91%
Novo-Nordisk A/S Newsroom
Express News | Can Simegluride also prevent cancer? Research shows that diabetic patients using this therapy have a lower risk of developing 10 types of cancer.
Small, Mid-size Biotechs Could See M&A Action in H2 - PwC
"Weight-loss miracle drug" has new benefits. Research shows that GLP-1 drugs may help reduce the risk of cancer.
The Centers for Disease Control and Prevention (CDC) in the USA states that obesity increases the risk of developing 13 cancers, while the latest research examines the health records of diabetes patients and finds that some diabetes treatments may help prevent obesity-related cancers.
U.S. stocks closed with the expectation of interest rate cuts boosted by non-farm payrolls, with the S&P and Nasdaq hitting new highs! Tesla rose nearly 38% in eight days, while Nvidia cooled off.
In June, non-farm payroll employment in the USA fell sharply, with significant downward revisions to previous data, and the unexpected rise in unemployment rate highlighted a cooling labor market, leading the market to bet over 70% on rate cuts in September and December.
The Trader: Conagra Took a GLP-1 Hit. Why Its Stock Is Worth a Look. -- Barron's
By Paul R. La Monica Ozempic and other popular injectable GLP-1 drugs aren't just helping dieters shed pounds. They're also leading to share price losses for top food stocks. Take a look at Conagra B
Novo Nordisk's (NYSE:NVO) Ozempic Linked to Lower Risk of Cancer
Study Links GLP-1 Drugs, Metformin to Lower Risk of Certain Cancers
Shares of Lilly and Novo Nordisk Are Trading Higher Following a Study Showing Patients Taking GLP-1 Treatments Have a Reduced Risk of Developing Obesity-related Cancers.
Shares of Lilly and Novo Nordisk Are Trading Higher Following a Study Showing Patients Taking GLP-1 Treatments Have a Reduced Risk of Developing Obesity-related Cancers.
GLP-1 Treatments Such As Wegvoy, Mounjaro Cut Obesity-Related Cancer Risks, Study Finds
In a study published in JAMA Network, patients with type 2 diabetes taking GLP-1 treatments have a reduced risk of developing ten types of obesity-related cancers compared to those on insulin and othe
Ozempic Maker Novo Nordisk Reprimanded by UK Regulators for Payment Disclosure Failures
Novo Nordisk A/S (NYSE:NVO), the maker of the popular obesity drug Ozempic, has been reprimanded by the U.K.'s Prescription Medicines Code of Practice Authority (PMCPA) for failing to disclose fees an
Novo Nordisk Reprimanded in UK Over Undisclosed Payments; Novartis, Pfizer Found in Breach of Industry Code
Novo Nordisk (NVO) was publicly reprimanded Friday by industry regulators in the UK for not disclosing payments amounting to roughly 7.8 million pounds ($10 million) within a three-year period. The Pr
UK Pharmaceutical Trade Group Slams Novartis, Three Others for Breaches
The Association of the British Pharmaceutical Industry's Prescription Medicines Code of Practice Authority flagged four major pharmaceutical companies for breaching its regulations. The British trade
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading
European equities traded in the US as American depositary receipts were higher late Friday morning, rising 0.53% to 1,446.18 on the S&P Europe Select ADR Index. From continental Europe, the gainers we
'Ozempic May Lower Risk of Obesity-Related Cancers, Study Finds' - Bloomberg Law
'Ozempic May Lower Risk of Obesity-Related Cancers, Study Finds' - Bloomberg Law
Novo Nordisk Reprimanded in UK for Failure to Disclose Payments to Healthcare Sector
$100 Invested In This Stock 10 Years Ago Would Be Worth $600 Today
Novo Nordisk (NYSE:NVO) has outperformed the market over the past 10 years by 9.02% on an annualized basis producing an average annual return of 19.86%. Currently, Novo Nordisk has a market capitaliza
Novo Nordisk's Weight-Loss Drug Retains Safety Profile Despite Concerns -- Market Talk
1204 GMT - Novo Nordisk's semaglutide--the active ingredient in its blockbuster weight-loss and diabetes treatments--belongs to one of the most derisked therapeutic drug classes in history from a safe
A Harvard study shows that semaglutide is related to rare vision loss. Novo Nordisk (NVO.US) leads the weight loss drug concept stocks in decline.
A Harvard study shows that the weight loss drugs Ozempic and Wegovy from Novo Nordisk A/S may be associated with rare vision loss.
Can it cause blindness? Research shows that the weight loss drug Ozempic is related to a rare blindness condition, and weight loss drug concept stocks have fallen.
Hidden risk of rare blindness.
A Harvard study shows a link between weight loss drug Ozempic and rare vision loss, causing a nearly 5% drop in novo-nordisk a/s stocks.
Some doctors have pointed out that there is currently no evidence to prove a direct causal relationship between drug use and eye complications, as some cases only appear after several months of medication.